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Highlights: 
x Prevalence of APOE ε4 in Alzheimer’s disease has been underestimated in 
previous studies 
x Prevalence of APOE ε4 decreases with age in early AD, but not at the dementia 
stage 
x Prevalence of APOE ε4 is highest in Northern Europe 
x Education and sex did not affect the prevalence of APOE ε4 
 
Research in context: 
1. Systematic review: Previous studies examining the prevalence of APOE ε4 in AD 
have included patients based on clinical criteria, without using biomarker 
information. This may have led to an underestimation of the prevalence of APOE 
ε4 due to misdiagnosis. 
2. Interpretation: Our results demonstrate that PET or CSF evidence for the 
presence of amyloid-β is associated with a higher prevalence of APOE ε4 (66% 
versus 50-60 in previous studies). 
3. Future directions: Information on APOE ε4 status would improve algorithms to 
determine risk for amyloid-β positivity, for example to enrich clinical trials. 
Furthermore, similar studies in amyloid-β positive subjects should be performed 
to determine the prevalence of other AD susceptibility genes. 
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ABSTRACT 
INTRODUCTION: APOE ε4 is the major genetic risk factor for Alzheimer’s disease 
(AD), but its prevalence is unclear since earlier studies did not require biomarker 
evidence of amyloid-E (AE) pathology. 
METHODS: We included 3,451 AE+ subjects (853 AD-type dementia, 1,810 mild 
cognitive impairment (MCI), and 788 cognitively normal (CN)). Generalized 
estimating equation models were used to assess APOE ε4 prevalence in relation to 
age, sex, education and geographical location. 
RESULTS: The APOE ε4 prevalence was 66% in AD-type dementia, 64% in MCI 
and 51% in CN, and decreased with advancing age in AE+ CN and AE+ MCI 
(p<0.05), but not in AE+ AD dementia (p=0.66). The prevalence was highest in 
Northern Europe, but did not vary by sex or education.  
DISCUSSION: The APOE ε4 prevalence in AD was higher than in previous studies, 
which did not require presence of AE pathology. Furthermore, our results highlight 
disease heterogeneity related to age and geographical location.  
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1. Introduction 
Alzheimer’s disease (AD) is the most common type of dementia and a major 
cause of morbidity and mortality worldwide [1]. Pathological metabolism and 
accumulation of E-amyloid (AE) peptides is thought to be an initiating event in AD, 
leading to downstream spread of tau pathology, synaptic loss, neurodegeneration and 
cognitive decline [2-4]. The main risk factors for the development of AD are 
increasing age and the H4 allele of the apolipoprotein E (APOE) gene [5-7], the 
strongest genetic risk factor for sporadic AD [8, 9]. APOE encodes for apolipoprotein 
E, which is a major lipid transporting protein in the brain [10]. In humans, the gene 
exists in three allele variants called H2, H3, and H4. Compared to APOE H3/H3 (the 
most common genotype), APOE H4 heterozygosity increases the risk for developing 
clinical AD by about 3-4 times, and APOE H4 homozygosity by about 10-15 times [8, 
11]. The overall prevalence of APOE H4 positivity has been reported to be 
approximately 15-20% in the normal population [11, 12] and 50-60% in patients with 
AD dementia [8, 9, 13]. These numbers, however, vary widely and may depend on 
different characteristics of the study population, including ethnicity [14] and 
geographical location [13]. Additionally, most previous studies included clinically 
diagnosed AD patients, without neuropathological confirmation and/or supportive 
pathophysiological AD biomarkers. Studies applying cerebrospinal fluid (CSF) and 
positron emission tomography (PET) have revealed that a substantial proportion of 
patients with a clinical diagnosis of AD dementia have no evidence of AE-pathology 
[15-18], which makes underlying AD pathology highly unlikely. This mismatch 
between the clinical diagnosis and AE biomarkers seems especially prevalent in 
APOE H4 non-carriers, as illustrated by a clinical trial in which 36% of APOE H4-
negative patients with a diagnosis of “AD dementia” lacked AE-pathology as 
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determined by PET [19]. Earlier studies emphasize the importance of the matter, as 
APOE H4 was found to be more strongly associated with biomarker evidence of AE 
pathology (irrespective of clinical status) than a clinical diagnosis of AD [20]. 
Similarly, the effect size of APOE H4 increased if presence or absence of AE 
pathology was neuropathologically confirmed [21].   
Another critical point of previous studies is the focus on the dementia stage of 
AD. AD is believed to follow a long trajectory in which AE pathology is present and 
clinical symptoms gradually develop before the threshold for dementia is reached [22-
24]. Few studies have investigated APOE H4 positivity in prodromal AD[25], i.e. mild 
cognitive impairment (MCI) due to AD (AE-biomarker positive), but prevalence rates 
around 25-55% have been reported. Similarly, not many studies reported the 
proportion of APOE H4 carriers among people with preclinical AD, i.e. presence of 
AE pathology without clinical symptoms [26-29]. 
In the present study, we aimed to investigate the prevalence of APOE H4 
positivity across the clinical and preclinical spectrum of AD in a large sample of AE-
biomarker positive individuals, including cognitively normal controls (CN), MCI, and 
AD dementia. We also tested whether the prevalence of APOE H4 positivity varied by 
age, sex and geographical location. For comparison, we included a group of AE-
negative participants. 
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2. METHODS 
2.1 Participants 
We used data from the Amyloid Biomarker Study Group, which is a worldwide 
collaborative project on AE PET and CSF biomarkers in conjunction with 
demographic, clinical and genetic variables [5, 30, 31]. From all contributing sites, we 
received individual participant-level data on 9,480 individuals (3,903 CN, 4,189 MCI, 
1,359 probable AD dementia and 538 non-AD dementia). Since we aimed to 
investigate the prevalence of APOE H4 across the spectrum of AD, we applied the 
following selection procedure for this study: i) we excluded patients with a clinical 
diagnosis of non-AD dementia, ii) among CN, MCI or AD dementia participants, we 
selected AE-positive (AE+) individuals as determined by PET and/or CSF and their 
AE-negative (AE-) counterparts for comparison, and iii) we excluded individuals who 
lacked information on APOE H4 status. 
Normal cognition was defined as normal scores on cognitive tests, the absence 
of cognitive complaints (for which medical help was sought), or both [5, 31]. Some of 
the CN participants had subjective cognitive decline (SCD, n=533 [102 AE+, 431 AE-
]), defined as presence of a cognitive complaint but normal cognition on 
neuropsychological tests [32]. We combined SCD subjects with the other CN [24, 
33], except for one sub-analysis (paragraph 3.7). MCI and probable AD dementia 
were defined according to established diagnostic criteria [22, 23, 34]. AE- “AD 
dementia” cases most likely do not have AD as the underlying cause of their cognitive 
impairment, although it should be noted that AE biomarkers could misclassify 
subjects, especially when biomarker signals are close to the cut-offs [35, 36].  
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2.2 PET/CSF procedures 
Individual PET scans were dichotomized (AE+ or AE-) using quantitative thresholds 
or visual reads according to the method used at the study site [5, 30]. CSF biomarkers 
were dichotomized as negative (normal) or positive (abnormal) using study-specific 
cutoffs [5]. For AD dementia patients we only had PET data available [30]. For NC 
and MCI, we selected the first available biomarker in time if a participant had both 
PET and CSF data [5]. Detailed PET/CSF procedures for each site are presented in 
Supplemental Table 1. 
 
2.3 APOE genotyping 
By design, all participants in this study had data on APOE H4 status. For 2,955/3,114 
(95.5%) CN and 3,054/3,335 (91.6%) MCI subjects we had specific genotypes (e.g. 
H3/H4, in addition to APOE H4 status), which allowed breakdown into APOE H4 non-
carriers, heterozygotes and homozygotes. Specific genotypes were not available for 
AD dementia patients, as they were only collected for CN and MCI participants in our 
previous studies [5, 30]. 
 
2.4 Age, sex, education and geographical location 
Information on age at time of clinical assessment was available for all participants. 
There were missing data for sex (130/7,419, 1.8%) and years of education 
(1,137/7,419, 15.3%). We used a previously published classification system for 
geographical location [13] to divide the participants into Southern Europe (n=653[215 
AE+, 438 AE-]), Central Europe (n=832[343 AE+, 489 AE-]), Northern Europe 
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(n=1,667[792 AE+, 875 AE-), Australia (n=395[190 AE+, 205 AE-]), North America 
(n=3,359[1,292 AE+, 2,067 AE-]) or Asia (n=315[114 AE+, 201 AE-]). Some 
participants (n=637[303 AE+, 334 AE-], 8.1%) could not be classified, as they were 
included in a multicenter study that covered multiple geographical locations.   
 
2.5 Statistical analyses 
Baseline differences were assessed using analysis of variance (with post-hoc 
Bonferroni correction) and χ2 tests. The prevalence of APOE ε4-positivity was defined 
by calculating the percentage of APOE ε4-positive individuals of the total number of 
participants in each diagnostic group. Generalized estimating equations (GEE) were 
used to estimate the effects of age, sex, education and geographical location on the 
prevalence of APOE ε4-positivity. GEE was the method of choice for the study as it 
allows analysis of binary-correlated data, such that participant-level data from all 
cohorts can be modeled while simultaneously accounting for participants within 
studies. A logit link function for binary outcome with an exchangeable correlation 
structure was assumed to account for within-study correlation. Analyses were 
conducted using the total study population, unless specified otherwise. Age was 
entered as a continuous measure centered at the mean. We tested 2-way and 3-way 
interactions between variables, and these terms were retained in the model if they 
appeared significant by the Wald statistical test. The GEE derived unstandardized β-
coefficients and standard errors (SE) of the main effect were reported. Significance 
was set at p<0.05 (two-sided). SPSS software (IBM, version 23.0) was used for 
statistics. 
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3. RESULTS 
3.1 Participants 
Demographic and clinical information for each diagnostic group is provided in Table 
1. We included 7,419 subjects, among which 970 with a clinical diagnosis of AD 
dementia (853 AE+, 117 AE-), 3,335 with MCI (1,810 AE+, 1,525 AE-) and 3,114 
CN subjects (788 AE+, 2,326 AE-). Demographic differences among the diagnostic 
groups included fewer males in the CN group (p<0.05) and less education in the MCI 
group compared to the other groups (p<0.001). Furthermore, in the dementia group 
AE-status was only determined using PET, while in the MCI group the proportion of 
subjects with CSF data (78%) was greater than that in the CN group (64.9%). In AE+ 
individuals, comparisons within diagnostic groups between APOE ε4 positive and 
negative groups showed that the mean age was lower in APOE ε4-positive than in 
APOE ε4-negative CN and MCI patients (p<0.01) (Supplemental Table 2). 
Supplemental Table 3 shows the demographic and clinical characteristics of 
individuals tested versus not tested for APOE in the complete Amyloid Biomarker 
Study Group dataset [5, 30, 31]. 
 
3.2 Prevalence of APOE ε4 positivity 
In AE+ subjects, the prevalence of APOE ε4 positivity was 50.9% in CN, 63.5% in 
MCI and 66.1% in AD dementia (Table 1). The prevalence of APOE ε4-positivity 
was higher in AE+ MCI and AE+ AD dementia than in AE+ CN (p<0.001), but there 
was no difference between AE+ MCI and AE+ AD dementia (p=0.19). For 
comparison, the APOE ε4 prevalence in AE- subjects was 24.5% in CN, 27.9% in 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  10
MCI and 24.8% in AD dementia, which was significantly lower than in AE+ 
counterparts (all p<0.001).  
 
3.3 Prevalence of APOE ε4 positivity by age, sex, education and modality  
The prevalence of APOE ε4 positivity was lower at older age in AE+ CN (β for 
change in prevalence per year±standard error: -0.02±0.01, p<0.05, Figure 1) and AE+ 
MCI (β=-0.03±0.01, p<0.01). For example, at age 50, the prevalence of APOE ε4 
positivity was 61% in AE+ CN and 75% in AE+ MCI, compared to 42% and 47% at 
age 90, respectively (Supplemental Figure 1). There was no age effect in AD 
dementia (β=0.01±0.01, p=0.66). There was also no effect of age in AD dementia 
when excluding patients (n=91) with a known atypical presentation, which are 
typically associated with lower prevalence of APOE ε4 (β=0.00±0.01, p=0.99, 
Supplemental Figure 2). In AE- subjects, the prevalence of APOE ε4 also decreased 
with age in CN (β=-0.03±0.01, p<0.001; difference with AE+: p=0.62) and MCI (β=-
0.03±0.01, p<0.001; difference with AE-: p=0.82), but not in AD dementia (β=-
0.01±0.02, p=0.55; difference with AE+: p=0.19)). All effects described above were 
similar when adjusting for sex and education.  
In AE+ subjects, sex and education had no direct effects on APOE ε4 
positivity, either across or within diagnostic groups (all p>0.05). Furthermore, in AE+ 
subjects there was an interaction between age and sex (p<0.05), whereby prevalence 
decreased with age for women but not for men. Examining the three-way interaction 
with diagnosis revealed that the interaction between age and sex was present in MCI 
(p<0.01), and at trend level in AD dementia (p=0.053), but not in CN subjects 
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(p=0.26). In AE- MCI subjects, there was a trend towards greater prevalence of APOE 
ε4 positivity in women (β: 0.19±0.10, p=0.06). There were no direct of interaction 
effects for education and no interaction effects (all p>0.05). The prevalence of APOE 
ε4 positivity was higher for CSF than for PET only in AE- MCI subjects (χ2 = 6.68, 
p=0.01; Supplemental Table 4). See Supplemental Table 5 for an overview of all main 
and interaction effects.  
 
3.4 Prevalence of specific APOE genotypes in CN and MCI 
Next, we stratified CN (n=2,955 [751 AE+, 2,204 AE-]) and MCI (n=3,054 [1,638 
AE+, 1,416 AE-]) subjects with APOE genotype information available into groups of 
APOE ε4 non-carriers, APOE ε4 heterozygotes and APOE ε4 homozygotes, and 
divided them into quartiles according to age. Both in CN and MCI the proportion of 
APOE ε4 heterozygotes and APOE ε4 homozygotes decreased with advancing age 
(Figure 2). Prevalence of the specific genotypes (i.e. APOE ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, 
ε3/ε4 and ε4/ε4) is provided in Table 2.  
 
3.5 Prevalence of APOE ε4 positivity by geographical location 
Next, we assessed the effect of geographical location on prevalence of APOE ε4 
positivity. Within AE+ subjects, we found that the prevalence of APOE ε4 positivity 
across diagnostic groups was higher in Northern Europe compared to all other 
geographical locations except Australia (all p<0.001, Bonferroni corrected; Figure 
3A). In addition, the prevalence of APOE ε4 positivity was lower in Southern Europe 
compared to North America, Central Europe (p<0.05, uncorrected) and Australia 
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(p<0.001, Bonferroni-corrected), and higher in Australia than in Asia (p<0.05, 
uncorrected). Within AE- subjects, the prevalence of APOE ε4 positivity was higher 
in Northern Europe (p<0.001, Bonferroni-corrected) and Central Europe (p<0.05, 
uncorrected) compared to all other geographical locations (Figure 3B). These findings 
were similar when assessing each diagnostic group separately (Supplemental Figure 
3, Supplemental Table 5).  
 
3.6 Predictive effect of APOE ε4 status on disease stage 
Finally, to assess whether the APOE allele is predictive of AD dementia or MCI 
beyond its effect on AE, we performed binary logistic regression models, including 
age, sex, education, AE status (positive/negative) and APOE ε4 status 
(positive/negative) for CN vs MCI and CN vs AD.  We found that APOE ε4 status 
predicted both CN vs MCI (odds ratio [OR]: 1.629, 95% confidence interval [CI]: 
1.348-1.968, p<0.001) and CN vs AD (OR: 1.811, 95% CI: 1.457-2.251, p<0.001).  
 
3.7 Prevalence of APOE ε4 positivity by subjective cognitive decline 
The prevalence of APOE ε4 was higher in participants with SCD compared to those 
without, both among Aβ+ (64.7% vs 48.8%, p<0.05) and Aβ- (33.6% vs 22.4%, 
p<0.05) subjects (Supplemental Table 6). The relationship between age and APOE 
prevalence was not affected by the presence or absence of SCD (all p<0.05). 
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4. Discussion 
We found that the prevalence of APOE H4 positivity was 51% in preclinical AD (AE+ 
CN), 64% in prodromal AD (AE+ MCI) and 66 % in AE+ AD dementia. Among AE- 
subjects the prevalence of APOE H4 positivity was 25% in CN, 28% in MCI and 25% 
in AD dementia. Our estimates of APOE H4 prevalence in AE-biomarker verified AD-
type dementia are higher than reported in previous studies that defined AD-type 
dementia based on clinical criteria. This resonates well with studies examining the 
effect size of APOE H4 in pathology- or biomarker-confirmed cases [20, 21] and 
suggests that the prevalence of APOE H4 in AD-type dementia (66%) may have been 
underestimated in previous studies (50-60% [8, 9, 13]).  
Another main finding of this study was that the prevalence of APOE H4 
decreased with age in preclinical and prodromal AD. There are several possible 
explanations. First, the additive effects of APOE H4 and AE may have resulted in 
greater conversion from the CN and MCI groups to AD dementia.[37] Higher 
conversion rates could also be due to earlier and more pronounced accumulation of 
AE load in APOE H4 carriers [38], but the binary nature (AE positive or negative) of 
our dataset does not allow testing of this hypothesis. Second, supposedly due to the 
increased risk for cardiovascular diseases in H4 carriers, APOE H4 has been linked to 
increased mortality rates [39-41]. This observation fits our finding that APOE H4 
carriership also decreased with age in AE- CN and MCI subjects, although the 
reduction of APOE H4 in AE- subjects can also be caused by individuals transitioning 
from AE- to AE+ with advancing age. Finally, as APOE H4 accelerates the onset of 
amyloid aggregation by approximately 15 years [5, 26], the prevalence of H4 carriers 
in AE+ subjects will be higher at younger age ranges. Remarkably, the prevalence of 
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APOE H4 did not change with age in AD-type dementia. It may be hypothesized that 
the higher mortality in APOE H4 carriers is counterbalanced at the dementia stage by 
individuals transitioning from preclinical and prodromal AD into AD dementia. We 
also tested whether this lack of an age effect was caused by the inclusion of atypical 
variants of AD dementia as this group is characterized by lower prevalence of APOE 
H4 [42, 43], but this was not the case (Supplementary Figure 2). The pathogenesis of 
early-onset AD is complex since this group includes a mix of APOE H4-carriers who 
develop the disease at younger age and of APOE H4 non-carriers with rapidly 
progressive AD [44, 45]. This may confound relationships between APOE H4 and age, 
especially in young patients with AD-type dementia. Furthermore, it has been shown 
that the mortality effect of APOE H4 is less pronounced at older age [46], which may 
explain the lack of an age effect in AD dementia patients. It is not clear why AE+ 
women had decreasing prevalence of APOE H4 with age. However, a recent large 
meta-analysis also found an interaction between APOE H4, sex and age, so that APOE 
H4 conferred a greater risk for AD in women than in men at younger ages, but not in 
older [47]. It is possible that physiological changes around menopause may interact 
with APOE H4 in women and increase the risk for AE pathology in younger ages [48]. 
If this leads to an earlier onset of the disease, and earlier death, the APOE H4 
prevalence may appear to decrease with age in AE+ women. 
Another main finding was the lower prevalence of APOE H4 in both AE+ and 
AE- CN subjects compared to the MCI and dementia stages. This may be explained 
by a selection bias, as the vast majority of the MCI and AD dementia subjects visited 
a memory clinic, while many CN subjects were recruited as research volunteers. Also, 
APOE H4+ MCI patients may be more likely to seek medical help and APOE H4 
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carriers with dementia may be more willing to participate in research due to a positive 
family history. Another possible reason is that APOE H4 may accelerate the transition 
from preclinical to clinical AD. For example, APOE H4 may have an effect on brain 
structure and function through non-AE pathways [49-53], which may act 
synergistically with AE-pathology to shorten the time between start of AE deposition 
and cognitive decline. Thus, since APOE H4 carriers will develop symptoms earlier, 
prevalence of APOE H4 positivity in CN is lower than in MCI and dementia cases at 
the same age range. Finally, APOE H4 non-carriers (which would include APOE H2 
carriers) may have mechanisms of resilience (i.e., cognitive reserve) that are less 
present in H4 carriers [54]. 
We also found geographical differences in APOE H4 prevalence, with higher 
prevalence in AD patients from Northern Europe, Central Europe, and Australia, and 
lower prevalence in patients from Southern Europe and Asia. This is consistent with 
previous epidemiological studies in clinically diagnosed AD dementia and MCI 
patients [13, 55] and with lower prevalence of APOE H4 in the general population in 
Southern Europe and Asia compared to Northern Europe [14, 55-57]. The novelty of 
this study is that we confirm these geographical differences in AE-biomarker defined 
AD and throughout the continuum from preclinical to prodromal and dementia stages. 
The different geographical prevalence of APOE H4 may be important for recruitment 
of participants in clinical trials and for the use of APOE H4 in algorithms to predict 
AE-positivity [58]. 
Strengths of this study include the large number of AE-positive subjects across 
the spectrum from preclinical to prodromal and dementia stages of AD. Limitations 
include that relatively few participants came from Asia (n=315) and Australia 
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(n=394), and there were no participants from Africa and South America. There were 
no data on ethnicity of the participants, which may confound the results since 
ethnicity has been related to both APOE H4 and AD [14, 59]. Also, this study is based 
on an assembly of different study cohorts that may not be representative for typical 
memory clinic populations or the general population. Finally, AE-positivity was 
determined using different modalities (i.e. PET or CSF) and methods (e.g. visual read 
versus quantitative threshold for PET and different assays for CSF). There was an 
unexpected effect of CSF assay (Innotest vs Luminex), which could be interpreted as 
a cohort effect as the majority of subjects with CSF analyzed using the Luminex assay 
are ADNI participants (Supplemental Table 5).  We found no effects of modality 
(PET vs CSF) on APOE H4 prevalence, and in previous studies using these data we 
found only little evidence for heterogeneity related to modality and methodology [5, 
30]. 
With about 2/3 of prodromal AD and AD dementia patients being APOE H4 
carriers, our results further emphasize the importance of APOE H4 for the 
development of AD [8, 9]. This may be useful for development of disease-modifying 
treatments, which may be focused on attenuating the detrimental effects of APOE H4, 
and for understanding the molecular pathogenesis of AD [60]. Furthermore, the 
finding that the prevalence of APOE H4 decreases with age in CN and MCI subjects 
has potential implications for clinical trials in pre-dementia populations, as screening 
based on APOE status to enrich for AE-positivity may be less effective with 
advancing age. Last, it may be of importance to evaluate other proposed AD 
susceptibility genes [61] in cohorts with known AE status, as to date this has only 
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been assessed in cohorts of clinically diagnosed AD patients and cognitively normal 
elderly. 
 
5. Conclusions 
We have quantified the prevalence of APOE H4 in AE-biomarker defined preclinical 
AD, prodromal AD and AD dementia. The results emphasize the prominent role of 
APOE H4 in AD, but also point to disease heterogeneity, since APOE H4 positivity is 
markedly less common in elderly subjects in pre-dementia stages of AD and in people 
from specific geographical locations, including Southern Europe and Asia. Further 
studies on phenotypic differences between APOE H4-negative and APOE H4-positive 
AD patients may be important to understanding different pathways that may lead to 
AD, and ultimately to tailor disease-modifying treatments to specific patient 
subgroups. 
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FIGURE LEGENDS: 
 
Figure 1. Prevalence of APOE ε4 positivity by age, diagnosis and Aβ status 
Curves were plotted using the point estimates generated by generalized estimating equations 
and are within the age limits of the diagnostic groups. The models were adjusted for study 
(site) effect. The 95% confidence intervals are presented in eFigure 1in the Supplement. 
AD = Alzheimer’s disease; APOE = Apolipoprotein E 
 
Figure 2. Distribution of APOE ε4 negative, APOE ε4 heterozygous and APOE ε4 
homozygous subjects across different age quartiles (Fig-2A; Q1= <67 years, Q2= 67-73.2, 
Q3= 73.21-78.76, Q4= >78.77 years: Fig-2B; Q1= <66.67 years, Q2= 66.68-72.28, Q3= 
72.29-77.19, Q4= >77.2: Fig-2C; Q1= <59.5 years, Q2= 59.5-67.1, Q3= 67.11-75.65, Q4= 
>73.66 years; Fig-2D; Q1=<62 years, Q2= 62.01-68.41, Q3= 68.42-75.0, Q4= >75.01 years).  
Aβ = Amyloid-beta; APOE = Apolipoprotein E; Q = Quartile. 
 
Figure 3. Distribution of APOE ε4 negative and APOE ε4 positive subjects by geographical 
location for all Aβ+ (A) and Aβ- (B) participants across diagnostic groups. A further 
breakdown into diagnostic groups is provided in eFigure 2 in the Supplement. 8.1% of 
participants (n=637 [303 AE+, 334 AE-]) could not be classified, as they were included in a 
multicenter study that covered multiple geographical locations.   
Aβ = Amyloid-beta; APOE = Apolipoprotein E 
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